| Literature DB >> 36192753 |
Bochra Khadija1,2,3, Khouloud Rjiba1,2,3, Sarra Dimassi1,3, Wafa Dahleb1,2, Molka Kammoun1, Hanen Hannechi1, Najoua Miladi4,5, Neziha Gouider-Khouja6, Ali Saad1,3, Soumaya Mougou-Zerelli7,8.
Abstract
BACKGROUND: Corpus callosum malformations (CCM) represent one of the most common congenital cerebral malformations with a prevalence of around one for 4000 births. There have been at least 230 reports in the literature concerning 1q43q44 deletions of varying sizes discovered using chromosomal microarrays. This disorder is distinguished by global developmental delay, seizures, hypotonia, corpus callosum defects, and significant craniofacial dysmorphism. In this study, we present a molecular cytogenetic analysis of 2 Tunisian patients with corpus callosum malformations. Patient 1 was a boy of 3 years old who presented psychomotor retardation, microcephaly, behavioral problems, interventricular septal defect, moderate pulmonary stenosis, hypospadias, and total CCA associated with delayed encephalic myelination. Patient 2 was a boy of 9 months. He presented a facial dysmorphia, a psychomotor retardation, an axial hypotonia, a quadri pyramidal syndrome, a micropenis, and HCC associated with decreased volume of the periventricular white matter. Both the array comparative genomic hybridization and fluorescence in situ hybridization techniques were used.Entities:
Keywords: 1q43 microdeletion syndrome; Array CGH; Chromosomic abnormalities; Corpus callosum agenesis
Year: 2022 PMID: 36192753 PMCID: PMC9528098 DOI: 10.1186/s13039-022-00620-2
Source DB: PubMed Journal: Mol Cytogenet ISSN: 1755-8166 Impact factor: 1.904
Fig. 1The karyotype on the left a is for the patient 1 who has asymmetry on 1q and the karyotype on the right b is for patient 2
Fig. 244,0000 Agilent Technologies oligonucleotides array profiles of both patients showing: a deletion of at least 11,7 Mb in patient 1. b deletion of at least 2,7 Mb in patient 2
Fig. 3FISH analysis with commercial probes (a: Bluefish probe of telomere 1q: corresponding to the CEP170 gene and a control probe 1p36 in patient 1, b: green fluorescence probes corresponding to the PLD5 gene and a 1p36 red fluorescence control probe, c: confirmation of the interstitial deletion by performing FISH on the two q telomeres of the two homologous chromosomes 1 in patient 2). The white arrow shows the terminal deletion in patient 1 (a) and the interstitial deletion in patient 2 (b, c)
Phenotypic features of the two patients with deletion in 1q44 described in this study and those published earlier
| References | Boland | Hill et al. 2007 [ | Caliebe et al. 2010 [ | Zaki et al. 2012 [ | Nagmani et al. 2012 [ | Thierry et al. 2012 [ | Ballif et al. 2012 [ | Parlman et al. 2013 [ | Gupta et al. 2013 [ | Van et bon et al. 2008 [ | Gai et al.,2015 [ | Hemming et al. 2016 [ | Depienne et al. 2017 [ | Mohamed et al. 2018 [ | Córdova-Fletes et al. 2019 [ | Lloveras et al. 2019 [ | Present study | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Patients | 6 | 7 | 4 | 1 | 6 | 11 | 22 | 1 | 1 | 3 | 1 | 1 | 17 | 1 | 1 | 1 | 1 | 2 |
| Gender | 3F/4 M | 5F/2 M | 3F/1 M | M | 4F/2 M | 8F/3 M | 9 M/ 13F | F | F | M | M | M | 10F/7 M | F | M | M | M | M |
| Age | 2 -5 years | 6–18 years | 1- 2 years | 2 years | 2–17 years | 1–14 years | 2 years | 3 years | 14 years | 5 and ½ years old | 14 years | 1–22 years | 3 years | 3years2M | 9 years | 3 years old | 9 months | |
| FD | + | + | + | RF, PM, MIC, TUL, LSE, SYN | + in 3/6 | + | + | RF, TL, EP SFH, PM, SN, MIC, USP, T, LSE, WST | RF, HYP, SN | MIC, SN, TL, EP, USP, S, LSE, WST | RF, SN, USPF, WST, LSE, T | MIC, EP, USPF | + | RF, SFH, PM, MIC, SN, TL, USPF, LSE, WST | RF, SFH, PM, MIC, SN, T, USPF, WST, LSE, | - | RF, SFH, PM, SN, TL, EP, USPF, S, T, LSE, WST | RF, SFH, PM, HYP, MIC, SN, TL, EP, LSE, WST |
| Microcephaly | 4/6 | 6/7 | ¾ | + | 5/6 | 1,2 | 7/22 | - | + | + | + | + | + | + | + | + | + | + |
| DD/ID | + | 6/7 | + | 6/6 | + | – | – | + | + | + | – | + | + | + | + | + | - | |
| GR | – | 3/7 | – | – | – | – | + | – | – | – | – | – | – | + | + | + | + | |
| PD | + | – | + | – | + | – | + | + | + | + | – | + | + | + | + | + | + | |
| LR | – | – | 4/4 | + | – | 5/11 | – | – | – | + | + | – | + | + | – | + | + | - |
| BP | – | – | - | 2/6 | 4/11 | – | – | – | + | – | – | – | + | – | + | + | - | |
| Epilepsy | + | 6/7 | 4/4 | + | 2/6 | 11/11 | 10/22 | – | + | + | + | + | + | – | + | – | + | |
| Axial hypotonia | – | – | 4/4 | + | 1/6 | 4/11 | + | + | – | + | + | + | – | – | + | – | – | + |
| FD | – | – | – | – | – | – | – | + | – | + | + | + | – | – | – | – | – | – |
| GA | – | – | 1/4, Hypos | Hypog, AP | – | 2/11 Crypto | – | – | – | – | – | – | – | – | Bilateral crypto | – | hypos | Micropenis TE |
| CM | – | – | 2/4 VSD, ASD | – | 3/6 ASD, TOF, VSD | 1/11 | – | – | – | – | – | – | – | – | VSD, ASD | – | ISD, PS | – |
| OM | – | – | – | Clino | – | – | – | SHF | Polydac | Scoliosis | – | Scoliosis | – | Campto, GV, TV | – | Polydac | Polydac | |
| Brain IR | ACC: 5/6 | ACC: 6/7 | ACC in 4/4 | ACC | ACC in 4/6 | ACC in 1/11 | ACC in 7/22 | HCC Pach, Vent | HCC | HCC | Nle CC | P ACC | ACC in 15/17 | HCC | ACC | HCC | T CCA BA,DEM | HCC DVPWM |
| Deleted region | 1q42q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q44 | 1q43q44 | 1q44 | 1q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q43q44 | 1q42q43 |
| Deletion size (Mb) | 3,5 | 2 | 0,44 | 10,4 | 1,4 | 0,63 | 2 | 1,47 | 1,86 | 3,8 | 0,36 | 8 | 1,36 | 6,5 | 9,5 | 2,3 | 11,7 | 2,7 |
| GP: Start hg 18/19 (pb) | 243,100,000 | 243,000,000 | 244,968,377 | 238,681,384 | 242,987,737 | 244,900,000 | 243,433,377 | 242,191,892 | 244,744,522 | - | 243,651,534 | 241,183,190 | 243,100,00 | 242,664,760 | 239,721,730 | 243,011,722 | 235,500,506 | 240,470,722 |
| GP: End hg 18/19 (pb) | 245,715,000 | 245,000,000 | 245,394,377 | 249,190,989 | 244,331,570 | 245,100,000 | 245,433,377 | 243,660,791 | 246,608,189 | - | 24,4014,380 | 249,202,755 | 244,500,000 | 249,206,918 | 249,218,792 | 245,384,463 | 247,179,291 | 243,198,799 |
| Involved genes | ||||||||||||||||||
| Inheritance | – | De novo | De novo | De novo | De novo | De novo | – | De novo | – | De novo | – | – | – | De novo | De novo | |||
ACC: agenesis of corpus callosum, ASD: Atrial Septal Defect, BP: Behavioral Problems, BA: Brain Atrophy, CC: Corpus Callosum, CM: Cardiac Malformations, Clino: Clinodactyly, Campto: Camptodactyly, Crypto: Cryptorchidy, DD: Development Delay, DEM: Delayed Encephalopathic Myelination, DVPWM: Decreased Volume of the Periventricular White Matter, EP:Epicanthus, F: female, FD: Facial Dysmorphia, FD: Feeding Difficulties, GA: Genomic Positions, GA: Genital Anomalies, GV: Genu Valgum, Hypog: Hypogenitalism, Hypos: Hypospadias, HCC: Hypoplasia of corpus callosum, HYP: Hypertelorism, ID: intellectual deficiency, IR: Imaging Results, LR: Language Retardation, MIC:Micrognathia, M: male, OM: Other Malformations, PM: Protrusion of the metopic, RF: Round Face, TV: Talipes Valgus, TOF: Tetralogy of Fallot, TE: Testicular Ectopia, T ACC: Total Agenesis of the corpus callosum, P ACC: Partial Agenesis of the Corpus Callosum, Pach: Pachygyria, Vent: Ventriculomegaly, SFH: Short forehead, SN:Short nose with a broad root, THL: Thin upper lip, T:Telecanthus, UPSPF: Up slanted palpebral fissure VSD: ventricular septal defect, S:Strabismus, LSE: Low-set ears, WST: widely spaced teeth
Fig. 4Comparison of the size of the 1q deleted region, critical region, and involved genes in our patients and other studies. A schematic representation of the gene mapping at the 1q43q44 region is shown below the human chromosome pictogram
Fig. 5showing facial dysmorphia in both patients
Fig. 6Patient 1 brain MRI showing: total callosal agenesis (yellow arrow) and brain atrophy associated with delayed encephalic myelination